Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Leading cancer and infectious disease experts provide recommendations for both treatment and prevention of COVID-19 for people with cancer.
At the current pace, only about 20% of the world’s population will be vaccinated by the end of 2021.
Bamlanivimab and etesevimab may be given to people with mild to moderate COVID-19 who are at high risk for progression to severe disease.
Even as drugmakers ramp up supplies, only a trickle of the product has found its way into regular people.
Plitidepsin, derived from a sea squirt, may be far more potent than remdesivir against the coronavirus.
Full-dose anticoagulation treatment for moderately ill COVID-19 patients reduced the need for ventilators.
The ACTIV-2 study aims to determine whether neutralizing antibodies reduce the duration of COVID-19 symptoms.
Vaccines that stimulate immune responses against cancer using the mRNA technology may be fast-acting and cheap to make.
Bamlanivimab did not speed clinical improvement or reduce the time to hospital discharge or sustained recovery.
Two Phase III clinical trials are evaluating monoclonal antibodies for people hospitalized with moderate COVID-19.
The anti-inflammatory and antiviral drug combination reduced time to recovery for people hospitalized with COVID-19.
In Los Angeles County, daily new COVID cases, deaths and hospitalizations have soared beyond their previous highs.
Lies infected America in 2020. The very worst were not just damaging, but deadly.
Agency grants emergency authorization for antibody cocktail given to President Trump.
Arthritis drug Olumiant (baricitinib) can be used in combination with remdesivir.
Effective, early interventions would benefit individual patients and healthcare system.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.